ADHD Medication Titration and Monitoring: Finding the Right Dose Without Compromising Patient Safety

Adult ADHD Clinical Evidence Series | Article 5 | 21 November 2026

Dr Emmanuel Eni Amadi, PhD, MBA
Adult ADHD Clinician | GPhC-Registered Pharmacist Independent Prescriber | UKAAN-Trained | Medical Scientist
Founder & CEO | NeuroMET (the trading name for NeuroMetabolic Healthcare Ltd)
Founder & CEO | The Amadi Global Institute (TAGi)

Abstract

Background:

Pharmacological Treatment, aka, Medication, is an established treatment option for adults with attention deficit hyperactivity disorder (ADHD), but successful prescribing requires more than selecting a medicine. Individualised dose titration and ongoing monitoring are essential to balance symptom improvement, daily functioning, tolerability and patient safety.

Clinical focus:

This article examines ADHD medication titration, baseline assessment, cardiovascular monitoring, adverse effects, treatment adherence, shared decision-making and longer-term follow-up, drawing principally on the National Institute for Health and Care Excellence (NICE) guideline NG87.

Conclusion:

The goal of titration is not to achieve the highest possible dose. It is to identify an effective, tolerable and clinically appropriate treatment regimen that improves outcomes meaningful to the individual.

Keywords:

Adult ADHD; ADHD medication titration; ADHD medication monitoring; lisdexamfetamine; methylphenidate; atomoxetine; ADHD treatment; blood pressure; heart rate; patient safety; NICE NG87.

Introduction:

The Prescription Is Only the Beginning

For an adult who has spent years struggling with concentration, impulsivity, disorganisation or emotional regulation, receiving an ADHD diagnosis may provide a long-awaited explanation.

Starting treatment can bring another important question:

How do we know whether the medication is working - and whether the dose is right?

Some individuals experience noticeable improvement soon after starting stimulant medication. Others report only modest changes, troublesome adverse effects or benefits that do not last long enough to support their daily activities.

A patient might say:

“I can concentrate better in the morning, but by late afternoon I feel exhausted and irritable.”

Another might report:

“My attention has improved, but I am struggling to sleep and have lost my appetite.”

These experiences illustrate why ADHD medication requires structured clinical follow-up.

Prescribing is not a single event. It is a process of assessment, treatment initiation, careful dose adjustment, monitoring and review.

In the United Kingdom, NICE guideline NG87 - which I have labelled, “The Bible for ADHD”, establishes the importance of individualised titration and monitoring to achieve meaningful clinical benefit while minimising harm (NICE, 2018) [1].

1. What Is ADHD Medication Titration?

ADHD medication titration is the supervised process of adjusting a medicine's dose and, when necessary, its formulation or treatment regimen to identify an effective and tolerable treatment.

It generally begins with a dose appropriate to the individual medicine, patient characteristics and prescribing guidance. The clinician then evaluates response and adverse effects before deciding whether an adjustment is appropriate.

The objective is “Dose Optimisation”.

For ADHD clinical terms, Dose Optimisation is the process or steps of finding the right medication, the right formulation, the right dosing or frequency, and the right timing that maximises symptom relief and daily functioning while minimising side effects for that person. Just as our faces are different, so do people with ADHD metabolize and respond to ADHD medicines differently. As a result, clinicians will typically start with a low dose for each medication, and gradually adjust it upwards (titration) over several weeks, until maximum efficacy is observed.

According to NICE NG87, this means reducing ADHD symptoms while achieving positive changes in functioning and maintaining tolerable adverse effects [1].

Importantly, a higher dose does not necessarily produce a better outcome. This reminds me of a patient I had titrated with Lisdexamfetamine up to a maximum of 70mg once daily without a single, and effective symptom control. I had to switch her to Xaggitin XL 54 mg once daily, Mane - with or after a meal - x 30 tablets

Therefore, a patient may experience good symptom control at a lower dose. Another may require a different formulation or medicine rather than continued dose escalation.

The appropriate dose is determined by clinical response, safety, individual circumstances and informed patient preference—not simply by age, body weight or comparison with another person's prescription.

2. Why ADHD Medication Responses Differ Between Individuals

Adults with ADHD do not all respond to treatment in the same way.

Several factors influence medication selection and dose optimisation:

  • Individual differences in drug absorption, metabolism, and duration of action.

  • The severity and pattern of ADHD symptoms.

  • Coexisting anxiety, depression, autism or other neurodevelopmental conditions.

  • Cardiovascular health and other physical conditions.

  • Sleep patterns, appetite and nutritional status.

  • Daily responsibilities, including employment, study and family life.

  • Patient preferences, previous treatment experiences and tolerability.

For example, someone working regular daytime hours may have different treatment requirements from a healthcare professional undertaking rotating shifts.

A person who experiences persistent insomnia may require a different approach from someone whose principal difficulty is inadequate symptom coverage late in the day.

The formulation of a medicine also matters. Different methylphenidate preparations may have different release characteristics and should not automatically be treated as interchangeable.

NICE advises clinicians to consider the pharmacokinetic (PK) profiles of ADHD medicines and the variability of individual responses when prescribing [1].

This reinforces a fundamental principle:

ADHD medication should be tailored to the patient, not the patient forced to fit the medication.

3. What Should Happen Before ADHD Medication Is Started?

Safe titration begins before the first dose.

A comprehensive baseline assessment establishes the clinical information against which subsequent benefits and adverse effects can be evaluated.

NICE recommends reviewing the person's continuing need for ADHD treatment, relevant mental health and social circumstances, physical health, current medication, cardiovascular history and potential risks associated with prescribing [1].

A baseline assessment should consider:

ADHD symptoms and functioning: Which difficulties are causing the greatest impairment? What improvements would be meaningful to the patient?

Medical and medication history: Are there existing cardiovascular conditions, relevant drug interactions or other prescribing considerations?

Cardiovascular assessment: What are the patient's baseline blood pressure and pulse? Are there symptoms or historical findings that require further investigation?

Weight and nutritional status: Is there an existing concern about appetite, weight loss or disordered eating?

Mental health and sleep: Are there coexisting conditions that may influence treatment response, tolerability or the interpretation of symptoms?

Shared treatment goals: What does the patient hope medication will improve?

A routine ECG is not required for every person before ADHD medication, but NICE identifies circumstances in which further cardiovascular assessment or referral is appropriate [1].

This distinction matters. Safe prescribing requires appropriate investigation—not indiscriminate testing.

4. How Does the ADHD Medication Titration Process Work?

Titration should be undertaken by a healthcare professional with appropriate training and expertise in ADHD treatment.

Although the precise schedule depends on the medicine and clinical circumstances, the process generally follows five stages.

Stage 1: Establish the baseline

Document ADHD symptoms, functional impairment, physical observations, relevant adverse-effect risks and agreed treatment goals.

Stage 2: Initiate medication

Start the selected medicine at an appropriate dose, following its prescribing information, relevant formulary guidance and the patient's clinical circumstances.

Stage 3: Review response and tolerability

Rather than asking the patient whether their symptoms have improved and whether they are experiencing adverse effects, you have to be specific: Go through each of the symptoms to know which one has improved and which has not. Assessment should include daily functioning - not merely a symptom score.

For instance, if asking about sleep patterns, you may ask:

  • "Since adjusting your ADHD treatment, have you found it easier to wind down at bedtime and stick to a consistent sleep schedule?"

If you want to phrase it about mood, you can say:

"Have you noticed fewer sudden mood swings or feeling less overwhelmed during the day since starting your current ADHD dose?"

Stage 4: Adjust treatment when clinically indicated

The prescriber may maintain the current dose, adjust it, change the formulation or reconsider the medication.

Adjustments should be informed by the patient's response and relevant safety findings.

Stage 5: Confirm dose optimisation

Once an effective and tolerable regimen has been established, document the treatment plan and arrange appropriate ongoing monitoring.

NICE recommends regular specialist review during titration, giving weekly telephone contact as one example. Symptoms, impairment and adverse effects should be recorded at baseline and at dose changes [1].

For patients with coexisting neurodevelopmental, mental health or certain physical health conditions, NICE recommends slower titration and more frequent monitoring [1].

Patients should not independently increase, reduce or combine prescribed ADHD medication doses without advice from their prescriber.

5. Cardiovascular Monitoring: Why Blood Pressure and Heart Rate Matter

Cardiovascular monitoring is an important component of ADHD prescribing.

Stimulant medicines and atomoxetine can affect blood pressure and heart rate. These effects vary between individuals and require appropriate clinical assessment.

NICE recommends measuring heart rate and blood pressure:

  • Before and after each dose change.

  • Every six months during ongoing treatment.

  • More frequently when clinical circumstances justify additional monitoring.

NICE also recommends clinical action when certain significant cardiovascular abnormalities occur, including sustained resting tachycardia above 120 beats per minute, arrhythmia or clinically significant increases in systolic blood pressure confirmed on two occasions [1].

These findings require prescriber assessment and appropriate referral, rather than automatic continuation or further dose escalation.

Patients should promptly report concerning symptoms such as palpitations, fainting or unusual breathlessness. Chest pain or other potentially serious acute symptoms require urgent medical assessment.

The absence of noticeable symptoms does not replace blood pressure and pulse monitoring.

Equally, a minor change in pulse or blood pressure does not automatically mean treatment must be discontinued. Interpretation depends on the magnitude, persistence and clinical context of the finding.

6. Monitoring Appetite, Weight, Sleep and Emotional Wellbeing

ADHD medication monitoring must extend beyond cardiovascular observations.

Appetite and weight

Reduced appetite and weight loss may occur, particularly with stimulant medicines.

NICE recommends measuring adult weight every six months, with additional assessment when concerns arise [1].

Persistent weight changes may require dietary advice, changes in administration timing or a review of the treatment regimen.

Sleep

Sleep disturbance may reflect medication timing, duration of action, coexisting sleep difficulties or other factors.

A sleep diary can help identify patterns.

Simply increasing the dose to compensate for daytime tiredness may be inappropriate if the underlying issue is inadequate sleep.

Mood and emotional changes

Some individuals report irritability, anxiety, emotional changes or deterioration in wellbeing.

Clinicians should explore the timing of these experiences, their relationship to treatment and whether other mental health conditions require assessment.

New or severe psychiatric symptoms warrant prompt clinical review.

Other adverse effects

Headache, gastrointestinal symptoms and other tolerability concerns should also be discussed and documented.

The presence of an adverse effect does not always require treatment discontinuation, but it should never be dismissed without assessment.

The central question is whether the treatment continues to provide meaningful benefit with an acceptable safety and tolerability profile.

7. How Do We Know When the Dose Is Optimised?

An optimised ADHD medication dose is not defined by the number of milligrams prescribed.

It is defined by the balance of clinical benefit, functional improvement and tolerability.

Consider an adult who previously struggled to complete administrative work, maintain attention during meetings and organise daily responsibilities.

After treatment optimisation, that person may report:

  • Greater ability to complete important tasks.

  • Improved concentration and reduced distractibility.

  • Better management of impulsive responses.

  • More consistent functioning at work or home.

  • Acceptable sleep, appetite and general wellbeing.

However, a patient who experiences improved concentration but significant insomnia, persistent appetite suppression or clinically important cardiovascular changes may not have achieved satisfactory optimisation.

NICE explicitly includes improvements in education, employment and relationships within the intended outcomes of dose optimisation [1].

The best treatment outcome is not simply fewer symptoms. It is safer, more sustainable functioning in everyday life.

8. What Happens After Titration Is Complete?

Once medication is stabilised, ongoing review remains necessary.

NICE recommends that prescribing and monitoring following dose stabilisation take place under appropriate shared-care arrangements with primary care [1].

However, shared care requires agreement between the relevant clinicians and services. It should not be assumed that a GP has accepted responsibility simply because a specialist has recommended it.

A clear handover should specify the medicine, dose, monitoring requirements, responsibilities, review arrangements and procedures for managing concerns.

NICE recommends that a healthcare professional with training and expertise in ADHD management reviews medication at least annually [1].

The review should consider continued benefit, adverse effects, the patient's preferences, changes in circumstances and whether treatment remains appropriate.

An individual who has been stable for months may still require reassessment if their health, work demands, sleep, other medicines or personal circumstances change.

Dose stabilisation marks the transition to long-term care—not the end of clinical responsibility.

9. The Role of Pharmacist Independent Prescribers in ADHD Care

Pharmacist independent prescribers can contribute meaningfully to ADHD medication management when practising within their competence, clinical governance arrangements and applicable prescribing requirements.

Their pharmacological training is particularly relevant to medication optimisation, interaction assessment, adverse-effect monitoring, adherence and medicines safety.

However, an independent prescribing qualification alone does not establish specialist competence in ADHD diagnosis or treatment. Appropriate additional training, supervised experience, professional development and governance remain essential.

Drawing on more than 26 years of experience in pharmacy and healthcare, together with my medical sciences background, independent prescribing qualification and more recent specialist ADHD training and supervised clinical exposure, I regard medication monitoring as a critical component of responsible patient care.

A prescription should never be viewed in isolation from the person taking it.

Effective ADHD treatment requires clinical judgement, careful documentation, communication and an understanding of how treatment affects the individual's wider life.

10. What Patients Should Ask During an ADHD Medication Review

Patients should be encouraged to participate actively in treatment decisions.

Useful questions include:

  1. What improvements should I expect from this medication?

  2. How will we know whether the current dose is effective?

  3. What adverse effects should I monitor?

  4. When should my blood pressure, pulse and weight be checked?

  5. What should I do if the medicine affects my sleep or appetite?

  6. Who should I contact if I experience problems between appointments?

  7. What happens when my medication is stable?

  8. Who will be responsible for prescribing and monitoring in the longer term?

These questions help turn a medication review into a collaborative clinical discussion.

They also reinforce the importance of informed consent, accessible information and shared decision-making.

11. Implications for ADHD Services and Healthcare Governance

For healthcare organisations, safe titration requires more than a prescription template.

Services need clearly defined clinical responsibilities, accessible follow-up arrangements, reliable documentation, escalation pathways and systems for tracking monitoring requirements.

This is particularly important in remote ADHD services, where clinicians may rely on patient-reported observations, appropriately obtained physical measurements and communication between different healthcare providers.

Remote care can support access and continuity, but it must not compromise the quality of assessment or monitoring.

Service quality should therefore be evaluated through meaningful indicators, including monitoring completion, documentation quality, patient-reported outcomes, adverse-effect management and continuity of care.

Conclusion: The Right Dose Is the One That Works Safely

ADHD medication can improve attention, impulse control and everyday functioning, but its benefits depend on appropriate prescribing and ongoing clinical evaluation.

Titration is not a race towards a higher dose.

It is a structured process of finding the treatment that provides meaningful benefit while minimising avoidable harm.

Cardiovascular observations, sleep, appetite, weight, mental health and patient preferences all contribute to that decision.

The central principle is straightforward:

Effective ADHD treatment is not about prescribing more medication. It is about prescribing the right treatment, at the right dose, for the right person—with the right monitoring.

References

  1. National Institute for Health and Care Excellence (NICE) (2018) Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. Available at: https://www.nice.org.uk/guidance/ng87 (Accessed: 15 November 2026).

  2. Cortese, S. et al. (2018) ‘Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis’, The Lancet Psychiatry, 5(9), pp. 727–738. Available at: https://doi.org/10.1016/S2215-0366(18)30269-4

  3. Faraone, S.V. et al. (2021) ‘The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder’, Neuroscience & Biobehavioral Reviews, 128, pp. 789–818. Available at: https://doi.org/10.1016/j.neubiorev.2021.01.022

  4. National Institute for Health and Care Excellence (NICE) (2021) Shared decision making. NICE guideline NG197. Available at: https://www.nice.org.uk/guidance/ng197 (Accessed: 15 November 2026).

  5. National Institute for Health and Care Excellence (NICE) (2009) Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guideline CG76. Available at: https://www.nice.org.uk/guidance/cg76 (Accessed: 15 November 2026).

About the author

Dr Emmanuel Eni Amadi, PhD, MBA, is a medical scientist, GPhC-registered pharmacist independent prescriber and UKAAN-trained Adult ADHD Clinician. He is Founder and CEO of NeuroMetabolic Healthcare Ltd and The Amadi Global Institute, with interests in evidence-based ADHD care, clinical governance, medicines optimisation and executive education.

Professional enquiries: hello@neurometabolic.co.uk
Website: https://www.amadiglobal.com
TAGi training calendar: https://www.amadiglobal.com/training-calendar

Clinical disclaimer: This article provides general educational information and is not a substitute for individual clinical assessment, diagnosis or prescribing advice. ADHD medication initiation, adjustment and monitoring must be undertaken by appropriately qualified professionals in accordance with current guidance and individual clinical circumstances.

Next
Next

Healthcare Must Be Led by Those Who Understand It: Why Dr Tom Black’s Warning Demands the UK Government’s Action.